Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Role of Measurable Residual Disease (MRD) in Redefining Complete Response (CR) in Elderly Patients with Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial

Blood (2018) 132 (Supplement 1): 433.

https://doi.org/10.1182/blood-2018-99-113299

Published: 2018

Journal Articles

Imapct of Clonal Hematopoiesis of Indeterminate Potential (CHIP) Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome

Kiran Naqvi, MDMPH, Koji Sasaki, MD, Guillermo Montalban-Bravo, MD, Ana Alfonso, MD, Musa Yilmaz, MD, Nicholas J Short, MD, Rita Assi, MD, Elias J. Jabbour, MD, Farhad Ravandi, MD, Tapan M. Kadia, MD, Sherry A. Pierce, BSN, BA, Koichi Takahashi, MD, Graciela M. Nogueras González, MPH, Rashmi Kanagal-Shamanna, MD, Keyur P. Patel, MBBS, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2018) 132 (Supplement 1): 1814.

https://doi.org/10.1182/blood-2018-99-117112

Published: 2018

Journal Articles

Cell-Type Specific Mechanisms of Hematopoietic Stem Cell (HSC) Expansion Underpin Progressive Disease in Myelodysplastic Syndromes (MDS) and Provide a Rationale for Targeted Therapies

Blood (2018) 132 (Supplement 1): 1798.

https://doi.org/10.1182/blood-2018-99-116881

Published: 2018

Journal Articles

Prognostic Factors and Survival Outcomes in Blast Transformed Chronic Myelomonocytic Leukemia: A Mayo Clinic-MD Anderson Cancer Center Study of 171 Cases

Mrinal M. Patnaik, MDMBBS, Ana Alfonso, MD, Fevzi Yalniz, MD, Tapan M. Kadia, MD, Rangit Vallapureddy, MBBS, Elias Jabbour, MD, Terra L. Lasho, PhD, Curtis A. Hanson, MD, Hagop M. Kantarjian, MD, Ayalew Tefferi, MD, Guillermo Garcia-Manero, MD

Blood (2017) 130 (Supplement 1): 2964.

https://doi.org/10.1182/blood.V130.Suppl_1.2964.2964

Published: 2017

Journal Articles

Hematopoietic Architecture of MDS before and after Progression Reveals Two Biologically Distinct Disease Subtypes

Irene Gañán-Gómez, PhD, Ana Alfonso, MD, Yamini Ogoti, MS, Hui Yang, MD PhD, Guillermo Montalban-Bravo, MD, Abraham C Yu, BS, Matteo Marchesini, PhD, Carlos E Bueso-Ramos, MD PhD, Koichi Takahashi, MD, Karen Clise-Dwyer, PhD, Guillermo Garcia-Manero, MD, Simona Colla, PhD

Blood (2016) 128 (22): 4310.

https://doi.org/10.1182/blood.V128.22.4310.4310

Published: 2016

Journal Articles

Phase I Study of Ruxolitinib for Patients (Pts) with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Who Failed at Least One Line of Therapy

Yasmin Abaza, MD, Elias J. Jabbour, MD, Srdan Verstovsek, MD PhD, Zeev Estrov, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Tapan M. Kadia, MD, Naval Daver, MD, Courtney D DiNardo, MD, Carlos E. Bueso-Ramos, MD PhD, Juliana E. Hidalgo, MD, Heather Schneider, BSN, RN, Guillermo Montalban Bravo, MD, Ana Alfonso, MD, Yue Wei, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2016) 128 (22): 4318.

https://doi.org/10.1182/blood.V128.22.4318.4318

Published: 2016

Journal Articles

Immunotherapy with LAK Cells and Anti-CD20 Monoclonal Antibodies for Follicular Lymphoma: Enhanced Antibody-Dependent Cell Cytotoxicity of LAK Cells in Association with GA101 Rather Than Rituximab

Carlos Panizo, Susana Inoges, MD, PhD, Ascensión López Díaz de Cerio, Ph D, Ricardo García Muñoz, MD, Fernando Pastor, PhD, Carlos Grande García, MD, Mayte Olave, MD, PhD, Luis Palomera, MD, Jose J. Rifon, MD, Sara Barea, MD, Ana Alfonso, MD, Maurizio Bendandi, MD, PhD

Blood (2012) 120 (21): 4881.

https://doi.org/10.1182/blood.V120.21.4881.4881

Published: 2012

NARROW

Role of Measurable Residual Disease (MRD) in Redefining Complete Response (CR) in Elderly Patients with Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial

Imapct of Clonal Hematopoiesis of Indeterminate Potential (CHIP) Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome

Cell-Type Specific Mechanisms of Hematopoietic Stem Cell (HSC) Expansion Underpin Progressive Disease in Myelodysplastic Syndromes (MDS) and Provide a Rationale for Targeted Therapies

Prognostic Factors and Survival Outcomes in Blast Transformed Chronic Myelomonocytic Leukemia: A Mayo Clinic-MD Anderson Cancer Center Study of 171 Cases

Hematopoietic Architecture of MDS before and after Progression Reveals Two Biologically Distinct Disease Subtypes

Phase I Study of Ruxolitinib for Patients (Pts) with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Who Failed at Least One Line of Therapy

Immunotherapy with LAK Cells and Anti-CD20 Monoclonal Antibodies for Follicular Lymphoma: Enhanced Antibody-Dependent Cell Cytotoxicity of LAK Cells in Association with GA101 Rather Than Rituximab

Email alerts

ASH Publications

American Society of Hematology

Role of Measurable Residual Disease (MRD) in Redefining Complete Response (CR) in Elderly Patients with Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial

Imapct of Clonal Hematopoiesis of Indeterminate Potential (CHIP) Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome

Cell-Type Specific Mechanisms of Hematopoietic Stem Cell (HSC) Expansion Underpin Progressive Disease in Myelodysplastic Syndromes (MDS) and Provide a Rationale for Targeted Therapies

Prognostic Factors and Survival Outcomes in Blast Transformed Chronic Myelomonocytic Leukemia: A Mayo Clinic-MD Anderson Cancer Center Study of 171 Cases

Hematopoietic Architecture of MDS before and after Progression Reveals Two Biologically Distinct Disease Subtypes

Phase I Study of Ruxolitinib for Patients (Pts) with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Who Failed at Least One Line of Therapy

Immunotherapy with LAK Cells and Anti-CD20 Monoclonal Antibodies for Follicular Lymphoma: Enhanced Antibody-Dependent Cell Cytotoxicity of LAK Cells in Association with GA101 Rather Than Rituximab

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only